Merit Medical Systems Inc. filings document operating and financial results, Regulation FD disclosures and material events for a medical-device manufacturer serving interventional, diagnostic and therapeutic markets. Recent Form 8-K reports cover quarterly and annual results, conference-call materials, historical revenue information under the Foundational and Therapeutic product categories, and product-related updates.
The company’s proxy materials describe board composition, governance practices, executive compensation and shareholder voting matters. Other filed event reports address board-leadership changes, completed product-technology acquisitions, capital-structure disclosure categories and clinical or regulatory disclosures tied to Merit’s device portfolio.
MERIT MEDICAL SYSTEMS INC Chief Commercial Officer Christian Adam Smith reported an open-market purchase of 1,626 shares of Common Stock at $61.00 per share on May 11, 2026 through a 401(k) plan. Following this transaction, his indirect 401(k) holdings total 2,220 shares of Common Stock.
Separately, he holds 30,334 shares of Common Stock directly. He also holds non-qualified stock options to acquire 25,000 shares of Common Stock at an exercise price of $70.50 per share, expiring on October 4, 2028, and options to acquire 8,259 shares at an exercise price of $73.95 per share, expiring on March 31, 2030.
Merit Medical Systems director Lynne N. Ward reported an open-market sale of 5,000 shares of common stock on 2026-05-07. The weighted average sale price was $62.607 per share, from trades between $62.395 and $62.815. Ward now directly holds 7,809 shares.
Merit Medical Systems’ chief legal officer Brian G. Lloyd reported an insider purchase of company stock. On May 7, 2026, an entity described as a 401(k) plan bought 2,000 shares of common stock at $62.625 per share, recorded as indirect ownership.
Following this transaction, Lloyd’s filing shows 62,132 shares of common stock held directly, plus the 2,000 shares held through the 401(k) plan. He also retains several blocks of non-qualified stock options to buy common shares, with exercise prices ranging from $37.71 to $70.58 and expirations between 2027 and 2030.
Merit Medical Systems President and CEO Martha Goldberg Aronson bought 2,000 shares of the company’s common stock in an open-market purchase at $60.44 per share. After this transaction, she directly owns 49,792 shares, indicating a modest increase in her personal stake.
MMSI submitted a Form 144 notice to offer 5,000 Common shares for sale, listed with a 05/07/2026 date. The filing lists two restricted stock lots of 2,914 shares dated 06/17/2022 and 2,086 shares dated 05/18/2024.
MERIT MEDICAL SYSTEMS INC Chief Financial Officer and Treasurer Raul Parra Jr. reported an open-market purchase of 1,500 shares of common stock at $61.01 per share on May 6, 2026. After this transaction, he directly holds 58,843 shares of common stock.
He also has an indirect interest in 2,699 shares held through a 401(k) Plan, representing plan holdings as of May 5, 2026. In addition, he holds non-qualified stock options for 13,576 underlying shares at an exercise price of $70.58 expiring on February 28, 2030, and options for 9,070 underlying shares at $65.03 expiring on February 28, 2029.
MERIT MEDICAL SYSTEMS INC executive Michel J. Voigt, the Chief Human Resources Officer, reported an open-market purchase of company stock through a retirement plan. He bought 2,250 shares of common stock at $60.65 per share, held indirectly via a 401(k) Plan, bringing those plan holdings to 2,265 shares as of the reported date.
Voigt also reports 46,127 shares of common stock held directly. In addition, he holds non-qualified stock options covering 11,076 shares at $70.58, 4,046 shares at $65.03, and 2,420 shares at $56.25, which become exercisable in 25% annual installments and expire between 2028 and 2030.
Merit Medical Systems delivered higher profitability in the quarter ended March 31, 2026. Net sales rose to $381.9 million from $355.4 million, a 7.5% increase, with growth in both foundational and therapeutic product categories and across domestic and international markets. Gross margin held steady at 48.4%, while operating income increased to $44.2 million. Net income improved to $41.0 million, or $0.68 diluted EPS, compared with $30.1 million, or $0.49 diluted EPS, a meaningful step-up in earnings. Cash, cash equivalents and restricted cash reached $490.2 million, and the company reported strong liquidity with over $697 million of additional borrowing capacity on its revolving credit facility. During the quarter, Merit completed the $28 million sale of its DualCap product line, generating a $12.5 million pre-tax gain, and later announced a $140 million acquisition of View Point Medical to expand its tissue localization technologies.
Merit Medical Systems, Inc. reported solid first quarter 2026 results, with net sales of $381.9 million, up 7.5% from $355.4 million a year earlier. GAAP diluted earnings per share were $0.68 versus $0.49, and non-GAAP EPS rose 9% to $0.94.
GAAP gross margin held at 48.4%, while non-GAAP operating margin improved to 19.7% from 19.3%. Free cash flow increased 26% to $24.7 million. Revenue by product category grew 6% in Foundational and 10% in Therapeutic on a reported basis.
For full-year 2026, Merit guides total revenue to $1.612–$1.634 billion, implying 6.3–7.8% GAAP growth, and maintains non-GAAP EPS guidance of $4.01–$4.15, or 5–8% growth. Updated guidance incorporates the April 1 acquisition of View Point Medical’s OneMark System, expected to add $2–$4 million of 2026 revenue and dilute prior non-GAAP EPS guidance by about $0.05.
Merit Medical Systems Inc Schedule 13G: Vanguard Capital Management reports beneficial ownership of 3,109,720 shares of Common Stock, representing 5.23% of the class as of 03/31/2026. The filing states Vanguard has sole dispositive power over all 3,109,720 shares and sole voting power over 453,557 shares. The disclosure notes holdings include shares held for Vanguard funds and managed accounts and names related Vanguard affiliates.